Efficacy of combined BRAF-MEK inhibitor second-line therapy in patients with non-resectable or metastatic BRAFV600-positive melanoma after prior immunotherapy: A retrospective EUMelaReg multicenter study
Eva Ellebæk(Copenhagen University Hospital), Dirk Schadendorf(Essen University Hospital), D. Ziogas(National and Kapodistrian University of Athens), Rudolf Herbst(Helios Klinikum Erfurt), Christoffer Gebhardt(Universität Hamburg), Anna Mariuk-Jarema(National Institute of Oncology), Michael Weichenthal(Christian-Albrechts-Universität zu Kiel), Gergana Shalamanova-Deleva(Medical University Plovdiv), Christina H. Ruhlmann(University of Southern Denmark), Rasmus Blechingberg Friis(Aarhus University Hospital), Iva Gavrilova(University Hospital St. Ivan Rilski), Inge Marie Svane(Copenhagen University Hospital), Axel Hausschild, Viktor Šabarić(University Hospital Centre Zagreb), Dimitra Stefanou(National and Kapodistrian University of Athens), Selma Ugurel(Klinikum Bielefeld), Shaked Lev‐Ari, Alfonso Berrocal(Hospital General Universitario De Valencia), M. Donia(Copenhagen University Hospital), Ainara Soria(Hospital Universitario Ramón y Cajal), Amalia Anastasopoulou(National and Kapodistrian University of Athens), J Utikal(German Cancer Research Center), Igor Stojkovski(University Clinic of Traumatology), Luisa Piccin(University of Naples Federico II), Alessandro Marco Minisini, Helen Gogas(National and Kapodistrian University of Athens), Berna C. Özdemir(University Hospital of Bern), Margarita Majem(Hospital de Sant Pau), B. Dujović(Military Medical Academy), Claudia Pföhler(Saarland University), Lourdes Gutiérrez(Research Institute Hospital 12 de Octubre), Ronnie Shapira, Lars Bastholt(Odense University Hospital), Tomislav Duvančić(Sisters of Charity Hospital), Alexander Gerasimov(University Hospital St. Ivan Rilski), Ahmed Kontilev(Tokuda Hospital), Reinhard Dummer(University Hospital Zurich), Friedegund Meier(University Hospital Carl Gustav Carus), John Haanen(The Netherlands Cancer Institute), Peter Mohr(Elbe Kliniken Stade-Buxtehude), Henrik Schmidt(Aarhus University Hospital), Joanna Mangana(University Hospital Zurich), Nethanel Asher(Rabin Medical Center), Paolo Antonio Ascierto(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Amina Jalovčić Suljeviić(Clinical Center University of Sarajevo), Piotr Rutkowski(The Maria Sklodowska-Curie National Research Institute of Oncology), Paweł Teterycz(National Institute of Oncology), Imke von Wasielewski(Medizinische Hochschule Hannover), Patrick Terheyden(University Hospital Schleswig-Holstein)
Cited by 1
Related Papers
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma
|New England Journal of Medicine|2017|2.2k
Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study
|The Lancet|2018|1.7k
Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma
|New England Journal of Medicine|2019|1.4k
Genome-wide scan reveals association of psoriasis with IL-23 and NF-κB pathways
|Nature Genetics|2009|1.4k